Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5426-5435
DOI: 10.1021/acs.molpharmaceut.6c00510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 27.09.2026. Verfasst von Sezen Gul und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut Galien Paris-Saclay, CNRS, UMR 8612, Université Paris-Saclay, 91400Orsay, France. Hauptthemen laut MEDLINE: RNA, Small Interfering, STAT6 Transcription Factor, NF-KappaB Inhibitor alpha, Tumor-Associated Macrophages. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Institut National Du Cancer.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) are central regulators of the tumor microenvironment (TME). Their polarization state can critically influence tumor development and treatment resistance. In the TME, the pro-tumor M2-like phenotype is the most prevalent among TAMs and contributes to tumor progression by promoting immunosuppression, angiogenesis, and metastasis. Thus, reprogramming TAMs from an M2 to an antitumor M1-like phenotype is a promising strategy to enhance cancer immunotherapy by inhibiting these processes, stimulating inflammatory responses, and activating cytotoxic immune cells. In this study, an array of small interfering RNA (siRNA) targeting candidate genes to repolarize macrophages, i.e., the inhibitor of nuclear factor kappa B alpha (IκBα), the colony-stimulating factor 1 receptor (Csf-1r), and the signal transducer and activator of transcription 6 (Stat6), was delivered by lipid nanoparticles (LNPs). While knockdown of all targeted genes was successful, silencing IκBα or Stat6 altered M1/M2 marker expression toward an M1-like polarization. Furthermore, combining IκBα and Stat6 produced the most effective macrophage reprogramming, achieving simultaneous downregulation of M2 markers and upregulation of M1 markers. Our data demonstrates that this dual-targeting strategy strongly induced potent reprogramming of M2-polarized macrophages, establishing it as a superior immunotherapeutic framework.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Galien Paris-Saclay, CNRS, UMR 8612, Université Paris-Saclay, 91400Orsay, France.
- UMS-IPSIT-BIOINFO, Université Paris-Saclay, INSERM, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 91400Orsay, France.
- UMS-IPSIT-ACTAGEN, Université Paris-Saclay, Inserm, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 91400Orsay, France.
- UMS-IPSIT MIPSIT, Université Paris-Saclay, INSERM, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 91400Orsay, France.
- Université Paris-Saclay, Gustave Roussy, INSERM, Biothérapies Innovantes, 94805Villejuif, France.
- Institut Universitaire de France, Paris75231, France.
ORCID-Profile: Juliette Vergnaud, Séverine Domenichini, François Fay, Elias Fattal
Förderung
- Institut National Du Cancer
Zitieren
APA
Gul, S., Vergnaud, J., Wang, Q., Hery, M., Dumont, F., Tran, P., Domenichini, S., Deloménie, C., Cao, M., Achour, J., Perfettini, J. L., Fay, F., & Fattal, E. (2026). Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy. Molecular Pharmaceutics, 23(11), 5426-5435. https://doi.org/10.1021/acs.molpharmaceut.6c00510
Vancouver
Gul S, Vergnaud J, Wang Q, Hery M, Dumont F, Tran P, et al. Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy. Molecular Pharmaceutics. 2026;23(11):5426-5435. doi:10.1021/acs.molpharmaceut.6c00510
BibTeX
@article{Gul2026,
author = {Gul, Sezen and Vergnaud, Juliette and Wang, Qinglin and Hery, Mélanie and Dumont, Florent and Tran, Pauline and Domenichini, Séverine and Deloménie, Claudine and Cao, Mengyuan and Achour, Jihana and Perfettini, Jean-Luc and Fay, François and Fattal, Elias},
title = {Combined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5426--5435},
doi = {10.1021/acs.molpharmaceut.6c00510}
}
EUVIMED